# A Diagnostic Pitfall: Lupus Mastitis Presenting Before Diagnosis of Systemic Lupus Erythematosus

**Authors:** Saeed Rashaad Mohammed, Kavi Capildeo, Keisha Davis-King, Mickhaiel Barrow

PMC · DOI: 10.1155/crrh/5593452 · Case Reports in Rheumatology · 2026-02-17

## TL;DR

Lupus mastitis can appear before systemic lupus is diagnosed and may be mistaken for breast cancer, requiring careful evaluation for accurate diagnosis.

## Contribution

This case highlights lupus mastitis presenting prior to SLE diagnosis, emphasizing the need for awareness among clinicians.

## Key findings

- Lupus mastitis can mimic breast malignancy, leading to diagnostic challenges.
- Histopathology is often necessary to confirm lupus mastitis when clinical features are unclear.
- Antimalarials are the primary treatment, though no standardized protocol exists.

## Abstract

Lupus erythematosus panniculitis or lupus erythematosus profundus (LEP) is a rare manifestation of cutaneous lupus erythematosus, with an estimated prevalence of 2%–3% in those with either systemic lupus erythematosus (SLE) or discoid lupus erythematosus (DLE). LEP with involvement of the breasts is termed lupus mastitis (LM). Its presentation is heterogenous, with epidermal changes, erythema, violaceous skin changes, lipoatrophy, and ulceration with or without breast masses. LM may resemble breast malignancy; however, the clinical course, laboratory investigations, and imaging may often differentiate these. Should uncertainty still exist, LM may be confirmed on histopathology. LM is a chronic disease, and its natural course may include exacerbations and remissions. Antimalarial agents are the mainstay of treatment, whilst corticosteroids and cyclophosphamide have demonstrated utility. There is no standardized treatment protocol. We here present the case of a 50‐year‐old woman who was diagnosed with SLE and LM after several indeterminate breast biopsies with the intention of furthering awareness of this presentation.

## Linked entities

- **Chemicals:** cyclophosphamide (PubChem CID 2907)
- **Diseases:** systemic lupus erythematosus (MONDO:0007915), lupus erythematosus panniculitis (MONDO:0019561), discoid lupus erythematosus (MONDO:0019558), breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** mucin [NCBI Gene 100508689], KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}
- **Diseases:** leukopenia (MESH:D007970), axillary lymphadenopathy (MESH:D008206), splenomegaly (MESH:D013163), hemorrhage (MESH:D006470), autoimmune (MESH:D001327), vertigo (MESH:D014717), SPTL (MESH:C537503), cutaneous lupus erythematosus (MESH:D008178), benign masses (MESH:C536030), SLE (MESH:D008180), LM (MESH:D008413), systemic disease (MESH:D034721), LEP (MESH:D015435), Inflammation (MESH:D007249), trauma (MESH:D014947), fibrosis (MESH:D005355), Diabetic mastopathy (MESH:D005348), skin erythema (MESH:D012871), Hyperpigmentation (MESH:D017495), Idiopathic granulomatous mastitis (MESH:D058890), dyspnea (MESH:D004417), tumor (MESH:D009369), pancytopenia (MESH:D010198), anasarca (MESH:D004487), DLE (MESH:D008179), Lymphoma (MESH:D008223), fat necrosis (MESH:D005218), breast malignancy (MESH:D001943), infarction (MESH:D007238), granuloma (MESH:D006099), hypergammaglobulinemia (MESH:D006942), non-Hodgkin's lymphoma (MESH:D008228), Type 1 diabetes (MESH:D003922), diffuse large B-cell lymphoma (MESH:D016403), necrosis (MESH:D009336), benign breast diseases (MESH:D001941), erythema (MESH:D004890), IBC (MESH:D058922), mastalgia (MESH:D059373), anemia (MESH:D000740), portal vein thrombosis (MESH:D012170), neutropenia (MESH:D009503), breast (MESH:D061325), connective tissue disorders (MESH:D003240), hematologic abnormalities (MESH:D006402), hypertension (MESH:D006973), lipoatrophy (MESH:C535905), panniculitis (MESH:D015434), thrombocytopenia (MESH:D013921), lobular panniculitis (MESH:D018275), Ulceration of (MESH:D014456)
- **Chemicals:** cyclophosphamide (MESH:D003520), mycophenolate mofetil (MESH:D009173), Warfarin (MESH:D014859), double-stranded deoxyribonucleic acid (-), prednisolone (MESH:D011239), hydroxychloroquine (MESH:D006886), enoxaparin sodium (MESH:C000711671)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12915062/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12915062/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12915062/full.md

---
Source: https://tomesphere.com/paper/PMC12915062